KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Aurinia Pharmaceuticals (AUPH) Gross Profit (2020 - 2025)

Aurinia Pharmaceuticals' Gross Profit history spans 6 years, with the latest figure at $68.3 million for Q4 2025.

  • For Q4 2025, Gross Profit rose 25.78% year-over-year to $68.3 million; the TTM value through Dec 2025 reached $250.4 million, up 21.03%, while the annual FY2025 figure was $250.4 million, 21.03% up from the prior year.
  • Gross Profit reached $68.3 million in Q4 2025 per AUPH's latest filing, up from $65.3 million in the prior quarter.
  • In the past five years, Gross Profit ranged from a high of $68.3 million in Q4 2025 to a low of $866000.0 in Q1 2021.
  • Average Gross Profit over 5 years is $39.6 million, with a median of $41.2 million recorded in 2023.
  • Peak YoY movement for Gross Profit: surged 49600.0% in 2021, then decreased 10.47% in 2023.
  • A 5-year view of Gross Profit shows it stood at $22.9 million in 2021, then increased by 18.1% to $27.1 million in 2022, then soared by 46.64% to $39.7 million in 2023, then skyrocketed by 36.81% to $54.3 million in 2024, then rose by 25.78% to $68.3 million in 2025.
  • Per Business Quant, the three most recent readings for AUPH's Gross Profit are $68.3 million (Q4 2025), $65.3 million (Q3 2025), and $62.9 million (Q2 2025).